'Biopharma ecosystem is back to full health,' fueled by M&A: PwC

With pharma and life sciences deal values surpassing $65 billion in Q1, marking the strongest quarter in the industry since 2020, analysts from PwC have declared that the “biopharma ecosystem is ba | With pharma and life sciences deal values surpassing $65 billion in the first quarter, marking the strongest quarter in the industry since 2020, analysts from PwC have declared that the “biopharma ecosystem is back to full health.”